Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Strategic Science and Technologies LLC (SST) has announced the signing of an option agreement with one of the world’s largest over-the-counter (OTC) healthcare companies.
Subscribe to our email newsletter
The partner has received an exclusive option to obtain U.S. commercial rights to SST’s topical ibuprofen (SST-0225) upon its approval by the U.S. FDA.
SST-0225 is a patented topical cream product candidate containing ibuprofen, which incorporates SST’s KNOSIS™ delivery technology. It is currently in late-stage clinical development for the OTC treatment of acute pain. Financial terms were not disclosed.
"This transaction provides SST with a very strong commercial partner to bring this important product directly to individuals who suffer from acute pain," commented Eric T. Fossel, Ph.D., Scientific Founder and Chief Executive Officer of SST.
"The partner’s leadership in marketing and manufacturing high-quality healthcare products provides us with the widest distribution at an accessible price."
Locust Walk Partners served as exclusive transaction advisor, and Gunderson Dettmer served as legal counsel to SST.